Literature DB >> 9857962

Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia.

H Ishiguro1, T Ohtsuki, M Toru, M Itokawa, J Aoki, H Shibuya, A Kurumaji, Y Okubo, A Iwawaki, K Ota, H Shimizu, H Hamaguchi, T Arinami.   

Abstract

Several antipsychotic agents such as haloperidol and rimcazole are known to bind to sigma receptors with high affinity, and evidence for a potential link between sigma receptors and the etiology of schizophrenia has been reported. The present study was conducted to systematically search for nucleotide variants of the type 1 sigma receptor gene in 48 schizophrenics. Two polymorphisms were found: GC-241-240TT in the 5' flanking region and Gln2Pro. These two polymorphisms were in nearly complete linkage disequilibrium with each other. The Pro2 variant of the Gln2Pro polymorphism changes the endoplasmic reticulum retention signal motif. These polymorphisms were examined in an extended sample of schizophrenics (n = 308) and controls (n = 433) and a significant association between the presence of the TT/Pro2 haplotype and schizophrenia was observed (odds ratio = 1.27, P = 0.04).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9857962     DOI: 10.1016/s0304-3940(98)00797-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  18 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  Demonstration of a direct interaction between sigma-1 receptors and acid-sensing ion channels.

Authors:  Stewart M Carnally; Molly Johannessen; Robert M Henderson; Meyer B Jackson; J Michael Edwardson
Journal:  Biophys J       Date:  2010-04-07       Impact factor: 4.033

3.  A direct interaction between the sigma-1 receptor and the hERG voltage-gated K+ channel revealed by atomic force microscopy and homogeneous time-resolved fluorescence (HTRF®).

Authors:  Dilshan Balasuriya; Lauren D'Sa; Ronel Talker; Elodie Dupuis; Fabrice Maurin; Patrick Martin; Franck Borgese; Olivier Soriani; J Michael Edwardson
Journal:  J Biol Chem       Date:  2014-09-29       Impact factor: 5.157

4.  Overexpression of sigma1 receptor and its positive associations with pathologic TNM classification in esophageal squamous cell carcinoma.

Authors:  Qing-Xia Xu; En-Min Li; Yong-Fa Zhang; Lian-Di Liao; Xiu-E Xu; Zhi-Yong Wu; Jin-Hui Shen; Li-Yan Xu
Journal:  J Histochem Cytochem       Date:  2012-04-17       Impact factor: 2.479

Review 5.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  The pharmacology of sigma-1 receptors.

Authors:  Tangui Maurice; Tsung-Ping Su
Journal:  Pharmacol Ther       Date:  2009-07-18       Impact factor: 12.310

7.  Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins.

Authors:  S Kurosawa; E Hashimoto; W Ukai; S Toki; S Saito; T Saito
Journal:  J Neural Transm (Vienna)       Date:  2007-06-08       Impact factor: 3.575

Review 8.  Dopamine genes and schizophrenia: case closed or evidence pending?

Authors:  Michael E Talkowski; Mikhil Bamne; Hader Mansour; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2007-07-14       Impact factor: 9.306

9.  The σ-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1/GluN2A NMDA receptor.

Authors:  Dilshan Balasuriya; Andrew P Stewart; J Michael Edwardson
Journal:  J Neurosci       Date:  2013-11-13       Impact factor: 6.167

Review 10.  Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives.

Authors:  Francesca Serena Abatematteo; Mauro Niso; Marialessandra Contino; Marcello Leopoldo; Carmen Abate
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.